News Articles and Montana BioScience Alliance Newsletters
Golden Helix, Inc., a leading provider of clinical bioinformatics solutions, is pleased to announce that it has received CE mark approval for its genetic analysis platform VarSeq Suite. This significant regulatory milestone paves the way for the expansion of Golden Helix’s advanced genetic analytics products to the European market, ensuring compliance with the European Union’s health, safety, and environmental protection standards.
A new study of prion diseases, using a human cerebral organoid model, suggests there is a substantial species barrier preventing transmission of chronic wasting disease (CWD) from cervids—deer, elk and moose—to people.
Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, has announced the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis.
A team at Montana State University published research this week that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The work reveals a new process in human cells that has potential for treating a wide variety of genetic diseases. Postdoctoral researchers Artem Nemudryi and Anna Nemudraia conducted the research alongside Blake Wiedenheft, professor in the Department of Microbiology and Cell Biology in MSU’s College of Agriculture. The paper, titled “Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in […]
A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.
Congress has returned to Capitol Hill, and among the most important unfinished business on its agenda is agreeing to a new package to fight COVID-19 by funding second-generation vaccine research. When Congress left town, there was cautious optimism that a deal was close.
Thirty regional companies will be selected to present at the Rocky Mountain Life Sciences Investor & Partnering Conference. Companies seeking seed, early-stage, late-stage funding in the medical device, diagnostic, biotech, pharmaceutical, and digital health sectors are encouraged to apply.
With new labeling requirements, bioengineering entered consumer consciousness in a new way this year—but people are learning the benefits, according to Sarah Gallo, BIO’s VP of Agriculture and Environment, in this podcast.
From the NIne Questions for the World podcast, December 15, 2021. BIO President Michelle McMurray-Heath is interviewed by Richard Haass.
View the Spring 2024 Newsletter Newsletter now!
View the Winter II 2024 Newsletter now!